Biotech firm Immunocore, which traces its roots to Oxford spin-out Avidex, has signed a pre-clinical milestone payment deal with pharmaceutical giant GlaxoSmithKline (GSK) worth £142m ($212m) to develop the next-generation of cancer-fighting drugs. In addition, GSK will pay up to £200m ($300m) in development and commercial milestone payments for each product that reaches the market.…
Immunocore signs $212m GSK deal
Jul 11, 2013 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Feb 7, 2024
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024